Sun Pharma Faces U.S. Tariff Shock, HSBC Sees Limited Earnings Impact

Sun Pharma, India’s largest drugmaker, has come under focus after U.S. President Donald Trump announced a 100% import tariff on branded and patented pharmaceutical products, effective October 1, 2025. The move is expected to disrupt global pharma supply chains, but HSBC believes the earnings impact on Sun Pharma may be limited. The company reported $1.2 billion in global patented drug sales in FY25, of which $1.1 billion came from the U.S., contributing nearly 17% of revenue and 8–10% of EPS. Sun Pharma’s patented portfolio is led by psoriasis blockbuster Ilumya, whose drug substance is manufactured in South Korea and finished dosage in Europe—a fragmented supply chain that may complicate tariff compliance. HSBC highlights possible mitigation strategies, including shifting production to US-based CDMO partners, leveraging its three existing U.S. plants, or even acquiring new facilities. With over $3 billion in cash reserves, Sun Pharma has the financial strength to adapt, though execution could take 6–24 months. Despite near-term risks, HSBC maintains a Buy rating with a target price of ₹1,850, estimating a potential 8–10% downside to FY26–27 earnings if mitigation lags. An official response from Sun Pharma on the tariff announcement is awaited. #SunPharma #PharmaStocks #USIndiaTrade #Ilumya #StockMarketIndia #TariffImpact #Healthcare